Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.35, $0.16 better than the analyst estimate of $0.19. Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE